We investigated the impact of biparatopic FGFR2 antibody candidates bpAb-B/C and bpAb-B/D on 2 patient-derived models of FGFR2 fusion + ICC, ICC13-7 (FGFR inhibitor–sensitive), and ICC21 (partially sensitive) (28). The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.